ArticleBMJ case reports2019
Successful treatment of nasopharyngeal cancer using radiotherapy with concurrent cetuximab in a patient with Charcot-Marie-Tooth disease.
Article in BMJ case reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 3 citations in OpenAlex.
- Symptom clusters after chemoradiotherapy in discharged nasopharyngeal carcinoma patients.Frontiers in oncology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Herein we present a case of a patient with Charcot-Marie-Tooth (CMT) disease who was diagnosed with locally invasive nasopharyngeal carcinoma. In the context of CMT, the use of standard platinum-based radio-sensitising chemotherapy would have been neurotoxic and is contraindicated in patients with CMT. However, no alternate antineoplastic treatment strategies for patients with CMT have been described in the literature. In this case, an innovative approach was taken using radical radiotherapy concurrently with the biological agent cetuximab. The patient did not suffer any neurotoxicity, though he did experience several expected toxicities commonly associated with this regimen. The patient nonetheless completed treatment and has experienced an excellent response both clinically and radiographically and remains disease free.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.